• Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer
  • News
  • Contact
    • Directions

News

News Subscription

Apr 09. 2018
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Canada by Avir Pharma
Read more
Download
Mar 06. 2018
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Argentina by Grupo Biotoscana
Read more
Download
Mar 01. 2018
Basilea names Adesh Kaul as new member of its Management Committee
Read more
Download
Feb 27. 2018
Basilea reports significantly improved financial results in 2017
Read more
Download
Feb 23. 2018
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
Read more
Download
Feb 21. 2018
Basilea's CEO Ronald Scott will retire. Chief Commercial Officer David Veitch named as successor. Changes in the Board of Directors
Read more
Download
Jan 10. 2018
Basilea announces completion of the license agreement extension with Pfizer for antifungal Cresemba® for China and Asia Pacific
Read more
Download
Jan 03. 2018
Basilea reports start of clinical phase 1 study in collaboration with the U.S. Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma
Read more
Download
Dec 21. 2017
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of Staphylococcus aureus bacteremia (SAB)
Read more
Download
Dec 01. 2017
Basilea extends existing license agreement with Pfizer for antifungal Cresemba® (isavuconazole) to China and Asia Pacific
Read more
Download
  • previous
  • 1
  • …
  • 19
  • 20
  • 21
  • …
  • 32
  • next
  • Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer

Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

P: +41 61 606 11 11
E-mail: info@basilea.com

News subscription
  • Imprint
  • Terms of use and Privacy Notice
  • EFPIA Disclosure Code
  • Expanded Access Policy
  • Transparence des liens d’intérêt

© 2026 Basilea Pharmaceutica Ltd, Allschwil